---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-275384"
form_type: "8-K"
ticker: "BNTC"
cik: "0001808898"
company_name: "Benitec Biopharma Inc."
filed_at: "2023-11-13T23:59:59+00:00"
generated_at: "2026-06-08T05:21:13.989500+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Benitec Biopharma Q1 net loss $6M; 19 OPMD subjects enrolled; BB-301 dosing expected Dec/Jan

## Summary
- Net loss of $6.0M ($2.76 per share) vs $5.1M ($7.98 per share) in Q1 FY2023; higher share count reduced per-share loss.
- Cash and equivalents $25.9M at Sep 30, 2023, up from $2.5M at Jun 30, 2023, extending runway.
- R&D expense $4.4M (up 66% YoY) driven by BB-301 clinical development; G&A $1.6M (down 19% YoY).
- 19 subjects enrolled in OPMD Natural History Study as of Oct 2023; first BB-301 dose planned Dec 2023 or Jan 2024.
- FDA IND clearance received; Canadian REB submission completed; interim safety/efficacy data expected within 12 months of first dose.

## SEC filing metadata
- accession: 0001193125-23-275384
- form_type: 8-K
- ticker: BNTC
- cik: 0001808898
- company_name: Benitec Biopharma Inc.
- filed_at: 2023-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1808898/000119312523275384/0001193125-23-275384-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1808898/000119312523275384/d85932d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-275384
- JSON: https://secwatch.observer/filing/0001193125-23-275384.json
- Plain text: https://secwatch.observer/filing/0001193125-23-275384.txt

## Key facts
- Earnings Releases
  Benitec Biopharma Inc. reported First Fiscal Quarter ended September 30, 2023 results: revenue $0.
  - Period: First Fiscal Quarter ended September 30, 2023
  - Revenue: $0
  - Result: reported results
  source text: OPMD patient screening and enrollment to begin in Canada. Financial Highlights First Quarter 2024 Financial Results Total Revenues for the quarter ended September 30, 2023, were $0 compared to $0 for the quarter ended September 30, 2022. Total Expenses for the quarter ended September 30, 2023 were $5.9 million compared to $4.6 million for the quarter ended
  evidence_url: https://www.sec.gov/Archives/edgar/data/1808898/000119312523275384/0001193125-23-275384-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.